CancerDrs

Colorectal Cancer clinical trials in Florida

89 actively recruiting colorectal cancer trials at 42 sites across Florida.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 3 Recruiting Network

Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors

This phase III trial evaluates whether a web-based intervention called Current Together after Cancer (CTAC) works to increase the number of patients with surgically removed (resected) colorectal cancer who receive surveillance care that al…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT07018869
Sites in Florida:
  • Schulze Family Foundation Cancer Clinic - Bonita Health Center — Bonita Springs, Florida
  • Holy Cross Hospital — Fort Lauderdale, Florida
  • Regional Cancer Center-Lee Memorial Health System — Fort Myers, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

The purpose of this study is to compare how long the participants are disease-free (progression-free survival) when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, oxalipl…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06662786
Sites in Florida:
  • Florida Cancer Specialists South — Fort Myers, Florida
  • AdventHealth Medical Group Oncology and Hematology at Orlando — Orlando, Florida
  • Florida Cancer Specialists North Region — St. Petersburg, Florida
  • Florida Cancer Specialists East — West Palm Beach, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

The purpose of this study is to evaluate the efficacy and safety of standard-of-care chemotherapy and bevacizumab with or without INCA33890 in the first-line treatment of metastatic microsatellite stable colorectal cancer.

Sponsor: Incyte Corporation
NCT ID: NCT07284849
Sites in Florida:
  • Florida Oncology & Hematology — Fort Myers, Florida
  • University of Florida Health — Gainesville, Florida
  • Sylvester Comprehensive Cancer Center — Miami, Florida
  • Advent Health — Orlando, Florida
  • Orlando Health Cancer Institute Downtown Orlando — Orlando, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

The purpose of this study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with amivantamab and chemotherapy with 5-fl…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06750094
Sites in Florida:
  • Florida Cancer Specialists South — Fort Myers, Florida
  • Mount Sinai Medical Center Campus — Miami Beach, Florida
  • AdventHealth Cancer Institute — Orlando, Florida
  • Florida Cancer Specialists North Region — St. Petersburg, Florida
  • Florida Cancer Specialists East — West Palm Beach, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

This phase III trial compares hepatic arterial infusion (HAI) (pump chemotherapy) in addition to standard of care chemotherapy versus standard of care chemotherapy alone in treating patients with colorectal cancer that has spread to the li…

Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT05863195
Sites in Florida:
  • UM Sylvester Comprehensive Cancer Center at Aventura — Aventura, Florida
  • UM Sylvester Comprehensive Cancer Center at Coral Gables — Coral Gables, Florida
  • UM Sylvester Comprehensive Cancer Center at Deerfield Beach — Deerfield Beach, Florida
  • UM Sylvester Comprehensive Cancer Center at Hollywood — Hollywood, Florida
  • University of Miami Miller School of Medicine-Sylvester Cancer Center — Miami, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

The primary purpose of this study is to evaluate the efficacy of perioperative dostarlimab compared with standard of care (SOC) in participants with untreated T4N0 or Stage III (resectable), defective mismatch repair/ microsatellite instab…

Sponsor: GlaxoSmithKline
NCT ID: NCT05855200
Sites in Florida:
  • GSK Investigational Site — Deerfield Beach, Florida
  • GSK Investigational Site — Fort Lauderdale, Florida
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

The purpose of this study is to evaluate the safety and efficacy of pumitamig in combination with chemotherapy versus bevacizumab in combination with chemotherapy in participants with previously untreated, unresectable, or metastatic color…

Sponsor: Bristol-Myers Squibb
NCT ID: NCT07221357
Sites in Florida:
  • Florida Cancer Specialists - East — Cape Coral, Florida
  • Florida Cancer Specialists - North — St. Petersburg, Florida
  • Moffitt Cancer Center — Tampa, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

Researchers are looking for other ways to treat locally advanced or metastatic colorectal cancer (mCRC) that is unresectable and has a gene mutation called KRAS G12C. Standard (or usual) treatments for this type of colorectal cancer may in…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06997497
Sites in Florida:
  • Florida Cancer Specialists - South ( Site 7002) — Fort Myers, Florida
  • Mayo Clinic in Florida ( Site 0092) — Jacksonville, Florida
  • Orlando Health Cancer Institute ( Site 0065) — Orlando, Florida
  • Florida Cancer Specialists - North ( Site 7001) — St. Petersburg, Florida
  • Florida Cancer Specialists - East ( Site 7000) — West Palm Beach, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)

This study aims to address the unmet medical need of participants with metastatic colorectal cancer (mCRC) who have previously been treated with irinotecan, oxaliplatin, a fluoropyrimidine, and bevacizumab, by demonstrating an overall surv…

Sponsor: EMD Serono Research & Development Institute, Inc.
NCT ID: NCT07549412
Sites in Florida:
  • Florida Cancer Specialists-Broadway — Fort Myers, Florida
  • Florida Cancer Specialists - St. Petersburg Bayfront — St. Petersburg, Florida
  • Florida Cancer Specialists East - FCS EAST - West Palm Beach — West Palm Beach, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer

Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess the adverse events and change in disease activity of telisotuzumab adizutecan plus bevacizumab compared to standard…

Sponsor: AbbVie
NCT ID: NCT07525206
Sites in Florida:
  • Moffitt Cancer Center /ID# 279325 — Tampa, Florida
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial

This phase III trial compares the addition of total ablative therapy to the usual systemic therapy versus the usual systemic therapy alone in treating patients with advanced colorectal cancer that has spread to up to 4 body sites (limited …

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05673148
Sites in Florida:
  • UM Sylvester Comprehensive Cancer Center at Coral Gables — Coral Gables, Florida
  • UM Sylvester Comprehensive Cancer Center at Coral Springs — Coral Springs, Florida
  • UM Sylvester Comprehensive Cancer Center at Deerfield Beach — Deerfield Beach, Florida
  • UM Sylvester Comprehensive Cancer Center at Doral — Doral, Florida
  • UF Health Cancer Institute - Gainesville — Gainesville, Florida
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with adv…

Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT03093116
Sites in Florida:
  • Memorial Healthcare System — Hollywood, Florida
  • Local Institution - 2113 — Tampa, Florida
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone an…

Sponsor: Artios Pharma Ltd
NCT ID: NCT04657068
Sites in Florida:
  • Florida Cancer Specialists — Fort Myers, Florida
  • Mayo Clinic (Florida) — Jacksonville, Florida
  • Cancer Specialists of North Florida — Jacksonville, Florida
  • Florida Cancer Specialists — Orlando, Florida
  • Florida Cancer Specialists — Sarasota, Florida
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…

Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Florida:
  • University of Miami - Sylvester Comprehensive Cancer Center — Miami, Florida
  • Advent Health — Orlando, Florida
  • Florida Cancer Specialists South — Port Charlotte, Florida
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC. The dose escalation part has been com…

Sponsor: Merus B.V.
NCT ID: NCT03526835
Sites in Florida:
  • Florida Cancer Specialists — Fort Myers, Florida
  • University of Florida — Gainesville, Florida
  • Sarah Cannon Research Institute (Lake Nona) — Orlando, Florida
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

This study is open to adults aged 18 years and older with different types of HER2+ cancer that has spread and cannot be removed by surgery. People can take part in this study if their tumours show HER2 aberrations and previous treatment wa…

Sponsor: Boehringer Ingelheim
NCT ID: NCT06324357
Sites in Florida:
  • Helios CR Inc — Lakeland, Florida
  • H. Lee Moffitt Cancer Center and Research Institute — Tampa, Florida
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.

Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06128551
Sites in Florida:
  • Florida Cancer Specialists — Sarasota, Florida
  • Moffitt Cancer Center and Research Institute — Tampa, Florida
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

This study will help find the most suitable dose of ASP546C in people with gastric cancer, gastroesophageal junction (GEJ) cancer, pancreatic cancer, and other specific solid tumors. GEJ is where the food pipe (esophagus) joins the stomach…

Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT07488676
Sites in Florida:
  • Miami Cancer Institute — Miami, Florida
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer

This is an open-label, randomized, multicenter Phase 2 study to assess the efficacy and safety of FOLFIRI + bevacizumab + pelareorep vs. FOLFIRI + bevacizumab in patients with RAS-mutated, MSS mCRC who have progressed after one prior line …

Sponsor: Oncolytics Biotech
NCT ID: NCT07446322
Sites in Florida:
  • Moffitt Cancer Center — Tampa, Florida
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

CRC is the third most common type of cancer diagnosed worldwide with developed countries at highest risk. The purpose of this study is to assess adverse events and change in disease activity when telisotuzumab adizutecan is given in combin…

Sponsor: AbbVie
NCT ID: NCT06820463
Sites in Florida:
  • AdventHealth Orlando /ID# 270789 — Orlando, Florida
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

The goal of this clinical trial is to evaluate FMC-376 in participants with advanced solid tumors with KRAS G12C mutations. This clinical trial will be conducted in 3 parts: Phase 1A (Dose Escalation), Phase 1B (Dose Expansion), and Phase …

Sponsor: Frontier Medicines Corporation
NCT ID: NCT06244771
Sites in Florida:
  • Florida Cancer Specialists and Research Institute — Lake Mary, Florida
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer

The purpose of this study is to assess the anti-tumor activity of amivantamab as a monotherapy (Cohorts A, B, and C), to assess the recommended phase 2 combination dose (RP2CD) of amivantamab when added to SoC chemotherapy (Ph1b cohorts) a…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT05379595
Sites in Florida:
  • H Lee Moffitt Cancer Center — Tampa, Florida
View on ClinicalTrials.gov →

Showing 25 of 89 trials with sites in Florida. See all colorectal cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-01